Delivering the Monday 20 May Keynote Address for the ATS 2025 International Conference, Professor Eric Alton, MD, lead of the UK Respiratory Gene Therapy Consortium (GTC) and Co-Founder of AlveoGene, compared the next wave of advancement in the treatment of cystic fibrosis (CF) with GTC partner Boehringer Ingelheim to a fundamental football (soccer) strategy—shots on goal.
He also highlighted the potential of the InGenuiTy® platform in some additional indications under development by AlveoGene such as neonatal surfactant protein deficiency and Alpha-1 antitrypsin (AAT) deficiency lung disease.
The full article can be found here.
